Business Context and Reporting Period
This Form 6-K filing is submitted by GSK plc and GlaxoSmithKline Capital Inc. for the month of September 2026, dated September 15, 2026. The registrants are foreign private issuers filing under Rule 13A-16 or 15D-16 of the Securities Exchange Act of 1934. The report serves to incorporate specific legal opinions by reference into the registrants' Registration Statement on Form F-3 (File Nos. 333-278205 and 333-278205-02).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding legal opinions and does not contain financial performance data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No operational or financial comparisons are included in this report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the incorporation of legal exhibits into a registration statement.
Important Facts for Investors
- The filing incorporates two legal opinions (Exhibits 5.1 and 5.2) from Cleary Gottlieb Steen & Hamilton LLP into the Form F-3 registration statement.
- Exhibit 5.1 is the opinion of special U.S. counsel, and Exhibit 5.2 is the opinion of special English counsel.
- The report is signed by Julie Brown, Chief Financial Officer and Executive Director of GSK plc, and Richard John Latchford, Vice President of GlaxoSmithKline Capital Inc.
- This document does not contain financial results or operational updates for the period.